2017 Breakthroughs in Neurology Conference | SAT06 - Neuroscience in the Clinic: Aging/Dementia

Date Saturday 01/14/17

Time 01:15 PM - 04:15 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type

Director(s) Karen H. Ashe, MD, PhD, Jamie L. Starks, MD

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be able to describe neuroimaging and CSF biomarkers currently available for clinical use; recognize indications and contraindications for use of biomarkers in the diagnosis of AD in current clinical practice; interpret biomarker profiles in the differential diagnosis of dementia syndromes; define the role of biomarkers in identifying the preclinical phase of AD and implications for development of preventative therapies; explain how biomarkers may guide future therapeutic interventions for AD; and understand how biomarkers enhance the power and efficiency of AD clinical trials.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse, Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Interactive, Audience Participation

Event Timeline
01:15 PM - 01:20 PM		Introduction Karen H. Ashe, MD, PhD
01:20 PM - 01:30 PM		Case Presentation Jamie L. Starks, MD
01:30 PM - 02:00 PM		Review of Biomarkers in Alzheimer's Disease William T. Hu, MD, PhD, FAAN
02:00 PM - 02:25 PM		Case Presentation Conclusion: The Use of Biomarkers to Classify Dementia Bruce L. Miller, MD, FAAN
02:25 PM - 02:45 PM		Implications of Biomarkers in the Future Treatment of Alzheimer's Disease William T. Hu, MD, PhD, FAAN
02:45 PM - 03:15 PM		Panel Discussion
03:15 PM - 04:15 PM		Curbside Consults

Faculty Disclosures
Karen H. Ashe, MD, PhD	No disclosure on file
Jamie L. Starks, MD	Dr. Starks has nothing to disclose.
William T. Hu, MD, PhD, FAAN	Dr. Hu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fujirebio. Dr. Hu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Beckman Coulter. Dr. Hu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apellis Pharmaceuticals. The institution of Dr. Hu has received research support from NIA. The institution of Dr. Hu has received research support from TMCity Foundation. The institution of Dr. Hu has received research support from Atlanta Family Foundation. The institution of Dr. Hu has received research support from Fujirebio Diagnostics.
Bruce L. Miller, MD, FAAN	Dr. Miller has nothing to disclose.

��ɫ��

��ɫ��